HBM Holdings’ 2025 Profit Surges as Global Pharma Alliances Deepen

HBM Holdings Ltd. ( (HK:2142) ) has provided an update.

HBM Holdings reported a sharp increase in revenue to US$157.98 million and profit to US$92.22 million for 2025, alongside a strengthened balance sheet with cash and cash equivalents rising to over US$403 million. The surge in earnings was accompanied by higher research and development spending and administrative costs, underscoring the Group’s aggressive reinvestment in innovation despite increased operating expenses.

During the year, the company cemented its position as a global antibody innovation partner through multiple high-profile strategic collaborations with AstraZeneca, Otsuka/Visterra, Pfizer and Bristol Myers Squibb. These agreements, which include equity investment, co-located innovation facilities and extensive licensing of its HCAb platform, provide substantial potential milestone and royalty streams, reinforcing HBM’s role in next-generation antibody and autoimmune therapeutics development.

The most recent analyst rating on (HK:2142) stock is a Hold with a HK$11.50 price target. To see the full list of analyst forecasts on HBM Holdings Ltd. stock, see the HK:2142 Stock Forecast page.

More about HBM Holdings Ltd.

HBM Holdings Limited is a Cayman Islands-incorporated biotechnology company listed in Hong Kong that focuses on discovering and developing next-generation multi-specific antibodies and related biologics. Through its fully owned subsidiary Nona Biosciences and its proprietary HCAb Harbour Mice technology platform, the Group targets immunology, oncology, autoimmune and other disease areas via innovative antibody, ADC and T-cell engager therapies for global pharmaceutical partners.

Average Trading Volume: 3,426,500

Technical Sentiment Signal: Buy

Current Market Cap: HK$11.18B

See more insights into 2142 stock on TipRanks’ Stock Analysis page.